Healtheconbot, 10 Jun 2015 #HealthEconJA Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for…
Healtheconbot, 10 Jun 2015 #HealthEconJA Cost-utility analysis of certolizumab pegol versus alternative tumour necrosis factor inhibitors available for…